Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]
2016436 citationsDavid M. Simpson, Mark Hallett et al.Neurologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Mark W. Green's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Green with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Green more than expected).
This network shows the impact of papers produced by Mark W. Green. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Green. The network helps show where Mark W. Green may publish in the future.
Co-authorship network of co-authors of Mark W. Green
This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Green.
A scholar is included among the top collaborators of Mark W. Green based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Mark W. Green. Mark W. Green is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
19 of 19 papers shown
1.
Green, Mark W.. (2021). Medication overuse headache. Current Opinion in Neurology. 34(3). 378–383.8 indexed citations
Green, Mark W., Robert P. Cowan, & Frederick G. Freitag. (2018). Chronic Headache.5 indexed citations
5.
Simpson, David M., Mark Hallett, Eric Ashman, et al.. (2016). Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]. Neurology. 86(19). 1818–1826.436 indexed citations breakdown →
6.
Green, Mark W.. (2012). Secondary Headaches. CONTINUUM Lifelong Learning in Neurology. 18(4). 783–795.5 indexed citations
Green, Mark W., et al.. (2005). Managing Your Headaches. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)).3 indexed citations
Green, Mark W.. (2003). Response From Green. Headache The Journal of Head and Face Pain. 43(10). 1118–1119.2 indexed citations
16.
Green, Mark W.. (2001). The exploding head syndrome. Current Pain and Headache Reports. 5(3). 279–280.19 indexed citations
17.
Green, Mark W., et al.. (2001). Managing Your Headaches. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)).1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.